Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical BCG RIVM versus TICE in high-risk superficial bladder carcinoma
2005-001775-35Phase 2Terminated
- Sponsor
- medac GmbH
- Start
- May 2007
- Modality
- Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial comparing BCG medac (RIVM strain) with OncoTICE (TICE strain) (2 arms). Primary endpoint: Recurrence-free survival rate at 12 months. Started May 2007; status: terminated.
02
Drugs
BCG MEDACbcg vaccine
Beyond the preview
Go deeper on 2005-001775-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001775-35.